Low expression of a few genes indicates good prognosis in estrogen receptor positive breast cancer

BMC Cancer

Volumn 9, Issue , 2009, Pages

  Buechler, Steven ^a  

^a UNIVERSITY OF NOTRE DAME   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 4 PHOSPHONOBUTYRIC ACID; CELL CYCLE PROTEIN 6; ESTROGEN RECEPTOR; MESSENGER RNA; MONOCLONAL ANTIBODY KI 67; SPERM ANTIGEN; SPERM ASSOCIATED ANTIGEN 5; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER RELAPSE; CANCER RISK; CANCER SURVIVAL; COHORT ANALYSIS; COMPUTER MODEL; CONTROLLED STUDY; GENE EXPRESSION; GENE TARGETING; GENETIC TRAIT; HUMAN; LYMPH NODE METASTASIS; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; PROBABILITY; PROGNOSIS; BIOSYNTHESIS; BREAST TUMOR; DISEASE COURSE; DISEASE FREE SURVIVAL; DNA MICROARRAY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; METASTASIS; MONTE CARLO METHOD; RECURRENT DISEASE; STATISTICAL MODEL;

BREAST NEOPLASMS; COHORT STUDIES; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MODELS, STATISTICAL; MONTE CARLO METHOD; NEOPLASM METASTASIS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROBABILITY; PROGNOSIS; RECEPTORS, ESTROGEN; RECURRENCE;

EID: 68349152442     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-9-243     Document Type: Article

References (33)

1. Fisher B Jeong JH Bryant J Anderson S Dignam J Fisher ER Wolmark N Breast NSA randomised clinical trials BP Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials Lancet 2004, 364(9437):858-68. 10.1016/S0140-6736(04)16981-X 15351193
2. Goldhirsch A Glick JH Gelber RD Coates AS Thürlimann B Senn HJ members P Meeting highlights: International expert consensus on the primary therapy of early breast cancer 2005 Ann Oncol 2005, 16(10):1569-83. 10.1093/annonc/mdi326 16148022
3. Eifel P Axelson JA Costa J Crowley J Curran WJ Deshler A Fulton S Hendricks CB Kemeny M Kornblith AB Louis TA Markman M Mayer R Roter D National Institutes of Health Consensus Development Conference Statement: Adjuvant therapy for breast cancer, November 1-3, 2000 J Natl Cancer Inst 2001, 93(13):979-89. 10.1093/jnci/93.13.979 11438563
4. Paik S Shak S Tang G Kim C Baker J Cronin M Baehner F Walker M Watson D Park T Hiller W Fisher E Wickerham D Bryant J Wolmark N A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer N Engl J Med 2004, 351(27):2817-26. 10.1056/NEJMoa041588 15591335
5. Paik S Tang G Shak S Kim C Baker J Kim W Cronin M Baehner FL Watson D Bryant J Costantino JP Geyer CE Wickerham DL Wolmark N Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer J Clin Oncol 2006, 24(23):3726-34. 10.1200/JCO.2005.04.7985 16720680
6. de Vijver MJV He YD van't Veer LJ Dai H Hart AAM Voskuil DW Schreiber GJ Peterse JL Roberts C Marton MJ Parrish M Atsma D Witteveen AT Glas A Delahaye L Velde van der T Bartelink H Rodenhuis S Rutgers ET Friend SH Bernards R A gene-expression signature as a predictor of survival in breast cancer N Engl J Med 2002, 347(25):1999-2009. 10.1056/NEJMoa021967 12490681
7. Buyse M Loi S van't Veer L Viale G Delorenzi M Glas AM d'Assignies MS Bergh J Lidereau R Ellis P Harris A Bogaerts J Therasse P Floore A Amakrane M Piette F Rutgers E Sotiriou C Cardoso F Piccart MJ Consortium T Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer J Natl Cancer Inst 2006, 98(17):1183-92. 16954471
8. Zujewski JA Kamin L Trial assessing individualized options for treatment for breast cancer: The TAILORx trial Future oncology (London, England) 2008, 4(5):603-10. 10.2217/14796694.4.5.603 18922117
9. Piccart-Gebhart MJ Sotiriou C Adjuvant chemotherapy-yes or no? Prognostic markers in early breast cancer Ann Oncol 2007, 18(Suppl 12):xIi2-7. 10.1093/annonc/mdm532 18083699
10. Cardoso F Veer LV Rutgers E Loi S Mook S Piccart-Gebhart MJ Clinical application of the 70-gene profile: The MINDACT trial J Clin Oncol 2008, 26(5):729-35. 10.1200/JCO.2007.14.3222 18258980
11. Hanahan D Weinberg RA The hallmarks of cancer Cell 2000, 100:57-70. 10.1016/S0092-8674(00)81683-9 10647931
12. Simpson PT Reis-Filho JS Gale T Lakhani SR Molecular evolution of breast cancer J Pathol 2005, 205(2):248-54. 10.1002/path.1691 15641021
13. Sorlie T Perou CM Tibshirani R Aas T Geisler S Johnsen H Hastie T Eisen M Rijn van de M Jeffrey S Thorsen T Quist H Matese J Brown PO Botstein D Lonning PE Borresen-Dale A Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications Proc Natl Acad Sci USA 2001, 98(19):10869-74. 58566 11553815 10.1073/pnas.191367098
14. Kapp AV Jeffrey SS Langerød A Børresen-Dale AL Han W Noh DY Bukholm IRK Nicolau M Brown PO Tibshirani R Discovery and validation of breast cancer subtypes BMC Genomics 2006, 7:231. 1574316 16965636 10.1186/1471-2164-7-231
15. Tibshirani R Hastie T Narasimhan B Chu G Diagnosis of multiple cancer types by shrunken centroids of gene expression Proc Natl Acad Sci USA 2002, 99(10):6567-72. 124443 12011421 10.1073/pnas.082099299
16. Leisch F FlexMix: A general framework for finite mixture models and latent class regression in R Journal of Statistical Software 2004, 11(8):1-18. http://www.jstatsoft.org/v11/i08/
17. Wu Z Irizarry R Gentleman RFMM A Model-Based Background Adjustment for Oligonucleotide Expression Arrays Journal of the American Statistical Association 2004, 99(468):909-917. 10.1198/016214504000000683
18. Irizarry R Wu Z Jaffee H Comparison of Affymetrix GeneChip expression measures Bioinformatics 2006, 22(7):789-794. 10.1093/bioinformatics/ btk046 16410320
19. Gong Y Yan K Lin F Anderson K Sotiriou C Andre F Holmes FA Valero V Booser D Pippen JE Vukelja S Gomez H Mejia J Barajas LJ Hess KR Sneige N Hortobagyi GN Pusztai L Symmans WF Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: A gene-expression profiling study Lancet Oncol 2007, 8(3):203-11. 10.1016/S1470-2045(07)70042-6 17329190
20. Sotiriou C Wirapati P Loi S Harris A Fox S Smeds J Nordgren H Farmer P Praz V Haibe-Kains B Desmedt C Larsimont D Cardoso F Peterse HL Nuyten DSA Buyse M de Vijver MJV Bergh J Piccart M Delorenzi M Gene expression profiling in breast cancer: Understanding the molecular basis of histologic grade to improve prognosis J Natl Cancer Inst 2006, 98(4):262-72. 16478745
21. Tordai A Wang J Andre F Liedtke C Yan K Sotiriou C Hortobagyi GN Symmans WF Pusztai L Evaluation of biological pathways involved in chemotherapy response in breast cancer Breast Cancer Res 2008, 10(2):R37. 2397539 18445275 10.1186/bcr2088
22. Colozza M Azambuja E Cardoso F Sotiriou C Larsimont D Piccart MJ Proliferative markers as prognostic and predictive tools in early breast cancer: Where are we now? Ann Oncol 2005, 16(11):1723-39. 10.1093/annonc/ mdi352 15980158
23. Fan C Oh D Wessels L Weigelt B Nuyten DSA Nobel A van't Veer LJ Perou CM Concordance among gene-expression-based predictors for breast cancer N Engl J Med 2006, 355(6):560-9. 10.1056/NEJMoa052933 16899776
24. Liontos M Koutsami M Sideridou M Evangelou K Kletsas D Levy B Kotsinas A Nahum O Zoumpourlis V Koulouk-oussa M Lygerou Z Taraviras S Kittas C Bartkova J Papavassiliou AG Bartek J Halazonetis TD Gorgoulis VG Deregulated overexpression of hCdt1 and hCdc6 promotes malignant behavior Cancer Res 2007, 67(22):10899-909. 10.1158/ 0008-5472.CAN-07-2837 18006835
25. Yang YC Hsu YT Wu CC Chen HT Chang MS Silencing of astrin induces the p53-dependent apoptosis by suppression of HPV18 E6 expression and sensitizes cells to paclitaxel treatment in HeLa cells Biochem Biophys Res Commun 2006, 343(2):428-34. 10.1016/j.bbrc.2006.02.166 16546135
26. Pollok S Bauerschmidt C Sänger J Nasheuer HP Grosse F Human Cdc45 is a proliferation-associated antigen FEBS J 2007, 274(14):3669-84. 10.1111/j.1742-4658.2007.05900.x 17608804
27. Rizki A Mott JD Bissell MJ Polo-like kinase 1 is involved in invasion through extracellular matrix Cancer Res 2007, 67(23):11106-10. 10.1158/ 0008-5472.CAN-07-2348 18056432
28. Du J Jablonski S Yen TJ Hannon GJ Astrin regulates Aurora-A localization Biochem Biophys Res Commun 2008, 370(2):213-9. 10.1016/ j.bbrc.2008.03.072 18361916
29. Scholzen T Gerdes J The Ki-67 protein: From the known and the unknown J Cell Physiol 2000, 182(3):311-22. 10.1002/ (SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9 10653597
30. Viale G Regan MM Mastropasqua MG Maffini F Maiorano E Colleoni M Price KN Golouh R Perin T Brown RW Kovács A Pillay K Ohlschlegel C Gusterson BA Castiglione-Gertsch M Gelber RD Goldhirsch A Coates AS Group IBCS Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer J Natl Cancer Inst 2008, 100(3):207-12. 10.1093/jnci/djm289 18230798
31. Karakaidos P Taraviras S Vassiliou LV Zacharatos P Kastrinakis NG Kougiou D Kouloukoussa M Nishitani H Pa-pavassiliou AG Lygerou Z Gorgoulis VG Overexpression of the replication licensing regulators hCdt1 and hCdc6 characterizes a subset of non-small-cell lung carcinomas: Synergistic effect with mutant p53 on tumor growth and chromosomal instability-evidence of E2F-1 transcriptional control over hCdt1 Am J Pathol 2004, 165(4):1351-65. 1618634 15466399
32. Habel LA Shak S Jacobs MK Capra A Alexander C Pho M Baker J Walker M Watson D Hackett J Blick NT Greenberg D Fehrenbacher L Langholz B Quesenberry CP A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients Breast Cancer Res 2006, 8(3):R25. 1557737 16737553 10.1186/bcr1412
33. Schmidt MHH Broll R Bruch HP Finniss S Bögler O Duchrow M Proliferation marker pKi-67 occurs in different isoforms with various cellular effects J Cell Biochem 2004, 91(6):1280-92. 10.1002/jcb.20016 15048881